Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

31. März 2022 08:00 ET | Quelle: Blue Note Therapeutics

New Study Finds Cancer-Related Anxiety and Depression are Costing Medicare $5B Annually

SAN FRANCISCO, March 31, 2022 (GLOBE NEWSWIRE) -- Blue Note Therapeutics today announced results from a study providing the largest and most comprehensive assessment to date of the impact of...
24. März 2022 08:00 ET | Quelle: Blue Note Therapeutics

Blue Note Therapeutics to Present Health Economic Data at NCCN 2022 Annual Conference

SAN FRANCISCO, March 24, 2022 (GLOBE NEWSWIRE) -- Blue Note Therapeutics today announced that new data from a health economic study of anxiety and depression in Medicare patients living with cancer...
03. Februar 2022 09:00 ET | Quelle: Blue Note Therapeutics

Blue Note Therapeutics Enters Licensing Agreement With University of Sydney for ConquerFear, a Cancer Survivorship Intervention

SAN FRANCISCO, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Blue Note Therapeutics, a prescription digital therapeutics company dedicated to easing the burden of cancer and improving outcomes, today announced...
06. Januar 2022 16:02 ET | Quelle: Blue Note Therapeutics

Blue Note Therapeutics Receives Breakthrough Device Designation for Prescription-Only Digital Therapeutic for Acute Myeloid Leukemia

SAN FRANCISCO, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Blue Note Therapeutics, a prescription digital therapeutics company dedicated to easing the burden of cancer and improving outcomes, today announced...